EP0701563A4 - Gene transfer for treating a connective tissue of a mammalian host - Google Patents

Gene transfer for treating a connective tissue of a mammalian host

Info

Publication number
EP0701563A4
EP0701563A4 EP94910861A EP94910861A EP0701563A4 EP 0701563 A4 EP0701563 A4 EP 0701563A4 EP 94910861 A EP94910861 A EP 94910861A EP 94910861 A EP94910861 A EP 94910861A EP 0701563 A4 EP0701563 A4 EP 0701563A4
Authority
EP
European Patent Office
Prior art keywords
mammalian host
connective tissue
product
gene encoding
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94910861A
Other languages
German (de)
French (fr)
Other versions
EP0701563A1 (en
Inventor
Joseph C Glorioso
Christopher H Evans
Paul D Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP0701563A1 publication Critical patent/EP0701563A1/en
Publication of EP0701563A4 publication Critical patent/EP0701563A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The subject invention concerns a method of introducing at least one gene encoding a product into at least one cell of a connective tissue of a mammalian host for use in treating the mammalian host including employing recombinant techniques to produce a DNA vector molecule which contains the gene encoding for the product and infecting the connective cell of the mammalian host using the DNA vector molecule using the gene coding for the product. A method is provided for introducing at least one gene encoding a product into at least one cell of a connective tissue of a mammalian host employing non-viral means. A method to produce an animal model for the study of connective tissue pathology is also disclosed. Additionally, this invention provides a method of using in vivo a gene encoding an extracellular interleukin-1 binding domain of an interleukin-1 receptor.
EP94910861A 1993-03-08 1994-03-07 Gene transfer for treating a connective tissue of a mammalian host Withdrawn EP0701563A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2775093A 1993-03-08 1993-03-08
US27750 1993-03-08
PCT/US1994/002414 WO1994020517A1 (en) 1993-03-08 1994-03-07 Gene transfer for treating a connective tissue of a mammalian host

Publications (2)

Publication Number Publication Date
EP0701563A1 EP0701563A1 (en) 1996-03-20
EP0701563A4 true EP0701563A4 (en) 1997-07-02

Family

ID=21839568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94910861A Withdrawn EP0701563A4 (en) 1993-03-08 1994-03-07 Gene transfer for treating a connective tissue of a mammalian host

Country Status (4)

Country Link
EP (1) EP0701563A4 (en)
JP (1) JPH08511507A (en)
CA (1) CA2157782A1 (en)
WO (1) WO1994020517A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
CA2139948C (en) * 1992-07-13 2001-12-04 Fred D. Ledley Targeting somatic gene therapy to joints
EP0690673A4 (en) * 1993-12-14 1996-05-29 Univ Pittsburgh Systemic gene treatment of connective tissue diseases
WO1996007739A2 (en) * 1994-09-09 1996-03-14 Neurocrine Biosciences, Incorporated Interleukin-1 type 3 receptors
US6239268B1 (en) 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
ES2099029B1 (en) * 1994-12-29 1998-01-01 Boeheringer Ingelheim Espana S USE OF THE PLASMIDE PMAMAFGF TO PREPARE VASORRELAJANTOS AND ANTI-HYPERTENSIVE DRUGS.
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
EP1009444A2 (en) * 1997-09-02 2000-06-21 Chiron Corporation Compositions and methods for treating arthritis utilizing gene therapy
JP2003501043A (en) 1999-05-28 2003-01-14 ターゲティッド ジェネティクス コーポレイション Methods and compositions for reducing levels of tumor necrosis factor (TNF) in TNF-related disorders
EP1939300A1 (en) 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CN103232539B (en) 2001-06-26 2015-06-03 安姆根弗里蒙特公司 Antibodies to opgl
WO2004022718A2 (en) 2002-09-06 2004-03-18 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
AR056806A1 (en) 2005-11-14 2007-10-24 Amgen Inc RANKL- PTH / PTHRP ANTIBODY CHEMICAL MOLECULES
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CN101918018B (en) 2007-11-14 2012-12-05 再生医药有限公司 Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (en) 2009-10-26 2012-08-01 上海交通大学 Application of interleukin-1 receptor antagonist and medicinal composition thereof
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2015087916A1 (en) * 2013-12-12 2015-06-18 国立大学法人三重大学 Transgenic non-human mammal expressing human mmp2
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176170A1 (en) * 1984-06-04 1986-04-02 Pasteur Merieux Serums Et Vaccins Herpes simplex virus as a vector
WO1992007943A1 (en) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Retroviral vectors useful for gene therapy
WO1992011359A1 (en) * 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education A truncated interleukin-1 receptor gene for the treatment of arthritis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319071A (en) * 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5180182A (en) * 1991-08-26 1993-01-19 Haworth James R Trailer hitch alignment device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176170A1 (en) * 1984-06-04 1986-04-02 Pasteur Merieux Serums Et Vaccins Herpes simplex virus as a vector
WO1992007943A1 (en) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Retroviral vectors useful for gene therapy
WO1992011359A1 (en) * 1990-12-20 1992-07-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education A truncated interleukin-1 receptor gene for the treatment of arthritis

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BANDARA, G. ET AL: "Gene transfer to synoviocytes: prospects for gene treatment of arthritis", DNA CELL BIOL. (1992), 11(3), 227-31 CODEN: DCEBE8;ISSN: 1044-5498, 1992, XP000671125 *
BANDARA, G. ET AL: "Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer", PROC. NATL. ACAD. SCI. U. S. A. (1993), 90(22), 10764-8 CODEN: PNASA6;ISSN: 0027-8424, 1993, XP002029933 *
BLAKE J. ROESSLER ET AL.: "Adenoviral-mediated gene transfer to rabbit synovium in vivo", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 92, no. 2, August 1993 (1993-08-01), pages 1085 - 1092, XP000671409 *
EVANS C H ET AL.: "Gene transfer to joints for arthritis therapy", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 16, no. F, April 1992 (1992-04-01), pages 46, XP000566580 *
EVANS C H ET AL: "SYNOVIAL CELL TRANSPLANTS FOR GENE TRANSFER TO JOINTS.", FIRST INTERNATIONAL CONGRESS OF THE CELL TRANSPLANT SOCIETY, PITTSBURGH, PENNSYLVANIA, USA, MAY 31-JUNE 3, 1992. TRANSPLANT PROC 24 (6). 1992. 2966. CODEN: TRPPA8 ISSN: 0041-1345, XP000577114 *
G. BANDARA ET AL.: "Intraarticular expression of IRAP by gene transfer", ARTHRITIS AND RHEUMATISM, vol. 35, no. 9, September 1992 (1992-09-01), pages S193, XP000563856 *
HUNG, G.L. ET AL: "Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium", GENE THER. (1994), 1(1), 64-9 CODEN: GETHEC, 1994, XP000671119 *
PAUL D. ROBBINS ET AL.: "Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis", ANNAL NEW YORK ACADEMY OF SCIENCES, vol. 716, June 1993 (1993-06-01), pages 26 - 29, XP000565748 *
See also references of WO9420517A1 *
XIANG GAO ET AL.: "A novel cationic liposome reagent for efficient transfection of mammalian cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 179, no. 1, 30 August 1991 (1991-08-30), ORLANDO, FL US, pages 280 - 285, XP000572654 *

Also Published As

Publication number Publication date
WO1994020517A1 (en) 1994-09-15
EP0701563A1 (en) 1996-03-20
CA2157782A1 (en) 1994-09-15
JPH08511507A (en) 1996-12-03

Similar Documents

Publication Publication Date Title
EP0701563A4 (en) Gene transfer for treating a connective tissue of a mammalian host
WO2002032962A3 (en) Compositions of human proteins and method of use thereof
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
EP2258722A3 (en) Antibodies to fibroblast growth factor-like (FGF-like) polypeptides
EP1798239A3 (en) G-protein coupled receptors and uses therefor
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
DE69632536D1 (en) VACCINALS FOR THE RESPIRATORY SYNCYTIAL VIRUS WITH NUCLEIC ACIDS
WO2000027994A3 (en) Chlamydia pneumoniae genome sequence
AU2001278797A1 (en) Expression vector using for animal cell
EP1053245A4 (en) 45 human secreted proteins
IL122206A0 (en) Adeno-associated virus vectors for gene expression
EP1281717A3 (en) Putative ion channel
WO2000017222A8 (en) 31 human secreted proteins
WO1998011221A3 (en) CAR, a novel coxsackievirus and adenovirus receptor
EP0744408A3 (en) Rhesus ob protein and DNA
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
CA2336261A1 (en) Cyclin e2 genes and proteins
WO1996007739A3 (en) Interleukin-1 type 3 receptors
WO2000008157A3 (en) Human anion transporter genes atnov
WO2000061774A3 (en) Bone morphogenic proteins
EP0805204A3 (en) Epididymis-specific receptor protein and its use
GB9622174D0 (en) Gene expression
EP1331265A3 (en) density enhanced protein tyrosine phosphatases
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROBBINS, PAUL, D.

Inventor name: EVANS, CHRISTOPHER, H.

Inventor name: GLORIOSO, JOSEPH, C.

RHK1 Main classification (correction)

Ipc: C12N 15/86

A4 Supplementary search report drawn up and despatched

Effective date: 19970521

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010509

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030319